Dose-related effects of the peroxisome proliferator methylclofenapate in rat liver

Environmental Toxicology and Pharmacology

Volumn 11, Issue 3-4, 2002, Pages 233-242

  Lake, Brian G ^a   Rumsby, Paul C ^a   Cunninghame, Morag E ^a   Price, Roger J ^a  

^a TNO BIBRA International Ltd   (United Kingdom)

Author keywords

Cell replication; Cytochrome P450; Hepatic peroxisome proliferation; Methylclofenapate; Rat liver; Transforming growth factor 1

Indexed keywords

BROXURIDINE; METHYLCLOFENAPATE; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFECT; FATTY ACID OXIDATION; GENE EXPRESSION; HEPATOMEGALY; LABELING INDEX; LIVER CELL; LIVER MICROSOME; LIVER TOXICITY; LIVER TUMOR; LIVER WEIGHT; MALE; NONHUMAN; OSMOTIC PUMP; PEROXISOME; PRIORITY JOURNAL; RAT;

EID: 0036297292     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1382-6689(01)00116-8     Document Type: Article

References (60)

1. Negative selection in hepatic tumor promotion in relation to cancer risk assessment
2. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis
3. Comparison of the acute and chronic mitogenic effects of the peroxisome proliferators methylclofenapate and clofibric acid in rat liver
4. Hepatic peroxisome proliferation in rodents and its significance for humans
5. Transforming growth factor-β1 as a signal for induction of cell death by apoptosis
6. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans
7. Central role of PPARα in the mechanism of action of hepatocarcinogenic preoxisome prolifertors
8. Human transforming growth factor-β complimentary DNA sequence and expression in normal and transformed cells
9. Differential splicing in the 3′ non-coding region of rat cytochrome P452 (P450 IVA1) mRNA
10. Peroxisome proliferator-activated receptors: Insight into multiple cellular functions
11. Comparison of the hepatic effects of nafenopin, methylclofenapate, Wy-14 643 and clofibric acid on peroxisome proliferation, cell replication and tumour formation in the rat
12. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
13. The genetic toxicology of the peroxisome proliferator class of rodent hepatocarcinogen
14. Changes in protein and mRNA levels of growth factor/growth factor receptors in rat livers after administration of phenobarbitone or methylclofenapate
15. Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver
16. Cytochrome P-450 induction by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid)
17. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-β1
18. Levels of transforming growth factor β and transformin growth factor β receptors in rat liver during growth, regression by apoptosis and neoplasia
19. Peroxisome proliferation in primary cultures of rat hepatocytes
20. Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: Role of PPARα and TNFα
21. Activation of a member of the steroid hormone receptor superfamily by peroxisome prolifertors
22. Liver tumour promotion and breast cancer chemoprevention: Common mechanisms
23. Modulation of insulin-like growth factor-II/mannose 6-phosphate receptors and transforming growth factor-β1 during liver regeneration
24. Regulation of mannose-6-phosphate/insulin-like growth factor-II receptors and transforming growth factor beta during liver tumor promotion with phenobarbital
25. Isolation and fractionation of total nucleic acids from tissues and cells
26. Preparation and characterisation of microsomal fractions for studies of xenobiotic metabolism
27. Role of oxidative stress and enhanced cell replication in the hepatocarcinogenicity of peroxisome proliferators
28. Mechanisms of hepatocarcinogenicity of peroxisome proliferating drugs and chemicals
29. Peroxisome proliferation: Current mechanisms relating to non-genotoxic carcinogenesis
30. Structure-activity relationships for chemically induced peroxisome proliferation in mammalian liver
31. The CYP4 family
32. Comparison of the hepatic effects of nafenopin and Wy-14 643 on peroxisome proliferation and cell replication in the rat and Syrian hamster
33. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset
34. Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-β1 gene expression in the rat, Syrian hamster and guinea pig
35. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
36. Evaluation of the genetic toxicity of the peroxisome proliferator and carcinogen methylclofenapate, including assays using muta™ mouse and big blue™ transgenic mice
37. Protein measurement with the Folin phenol agent
38. A single receptor binds both insulin-like growth factor II and mannose-6-phosphate
39. Phenobarbital selectively promotes initiated cells with reduced TGFβ receptor levels
40. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14 643) in rats
41. The transforming growth factor-β family
42. Differential effects of transforming growth factor-β on proliferation of normal and malignant rat liver epithelial cells in culture
43. Differential induction and regulation of peroxisomal enzymes: Predictive value of peroxisome proliferation in identifying certain nonmutagenic carcinogens
44. The CYP2B subfamily
45. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1
46. Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14 643
47. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans
48. Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators
49. Transforming growth factor-β receptors type I, II and III in phenobarbital-promoted rat liver tumours
50. Peroxisome proliferators: Mechanisms of adverse effects in rodents and molecular basis for species differences
51. Role of Kupffer cells and oxidants in signaling peroxisome proliferation-induced hepatocyte proliferation
52. Role of Kupffer cells in peroxisome proliferator-induced hepatocyte proliferation
53. 1 gene expression and insulin-like growth factor II/mannose-6-phosphate receptor gene expression in rat liver
54. Expression of base excision repair enzymes in rat and mouse liver is induced by peroxisome proliferators and is dependent upon carcinogenic potency
55. Effects produced by the non-genotoxic hepatocarcinogen methylclofenapate in dwarf mice: Peroxisome induction uncoupled from DNA synthesis and nuclearity changes
56. Peroxisome proliferator-activated receptors: Structures and function
57. A peroxisome proliferator-activated receptor-alpha (PPARα) cDNA cloned from guinea-pig liver encodes a protein with similar properties to the mouse PPARα: Implications for species differences in responses to peroxisome proliferators
58. Dose-related effects of the hepatocarcinogen, Wy-14 643, on peroxisome and cell replication
59. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver